Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech will bring insights on its latest technological advances in enhanced production of plasmid DNA to the World Vaccine Congress in Barcelona.
The enGenes team at WVC 2024 will use the event to share knowledge and data gained from multiple ongoing projects and seek new partners for its patented technology platforms for intracellular and extracellular manufacturing, antibiotic-free systems, and more.
Leading role
Senior enGenes scientists Dr. Natalia Danielewicz and Dr. Karl Hübler are participating in the congress event hoping to network and attract new collaborations for its accelerated expression processes that separate growth and production phases, enable long-term cultivation, and enhance stability.
“We are looking to get into conversations with people in search of new ways to embrace our technologies and adapt them to various vaccine applications,” said Dr. Danielewicz.
The enGenes team will highlight the potential of enGenes -eXcess™ technology to optimize the manufacturing of high-quality plasmid DNA for gene therapy and vaccine development as well as the -eXchange™ platform for antibiotic-free and resistance marker-free manufacturing of recombinant proteins and plasmid DNA. They will also emphasize the influential role of its -eXpress™ and -eXcite™ technologies in the drive towards greener continuous production of biologics, as part of the ECOnti consortium.
留言